Intelligencia
Applying machine learning in drug development.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
$12.0m | Series A | ||
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 167 % | 19 % | 295 % | 121 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Intelligencia AI is a health tech company that leverages artificial intelligence to revolutionize drug development in the pharmaceutical industry. By providing AI-driven insights, the company helps enhance clinical development, mitigate risks, and enable confident business decisions. Intelligencia AI serves many of the top global pharmaceutical companies, offering solutions built with comprehensive and precise data. Their services include real-time tracking of clinical programs, expert data curation, and quality control by biomedical professionals. The company's advanced algorithms provide accurate Probability of Technical and Regulatory Success (PTRS) assessments, validated retrospectively. Intelligencia AI operates in the health tech market, focusing on pharmaceutical clients who seek to improve their drug development processes. The business model revolves around offering AI-powered solutions and data analytics services, generating revenue through subscriptions and service fees from pharmaceutical companies.
Keywords: AI-driven, drug development, pharmaceutical, clinical development, risk mitigation, data analytics, biomedical, PTRS assessments, health tech, real-time tracking.